Futurity September 23, 2024
U. Buffalo

New research identifies the likely culprit that turns classical Klebsiella pneumoniae into a devastating, drug-resistant killer.

More than a decade ago, physicians around the world began reporting cases due to a new hypervirulent strain of Klebsiella pneumoniae, which could infect and severely sicken otherwise healthy people.

Thomas A. Russo at the University at Buffalo and the VA Western New York Healthcare System (VAWNYHS) was one of them. In 2011, he treated his first case in Buffalo, a young person with no other comorbidities who was hospitalized for months with this hypervirulent bacterium.

The patient fully recovered, but Russo became curious about this hypervirulent bacterium—and alarmed, given the fact that it was able to infect otherwise healthy individuals from the community...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Answer ALS, Cedars-Sinai Collaboration, Single-Cell Protein Profiling, ChapsVision Acquires Sinequa, More
Pharma Pulse 11/25/24: Deepening Patient Relationships,
Halozyme abandons its €2bn pursuit of Evotec
BridgeBio poised to challenge Pfizer after Attruby approval
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy

Share This Article